학술논문

Large-scale exploratory genetic analysis of cognitive impairment in Parkinson's disease.
Document Type
article
Source
Subject
Humans
Parkinson Disease
Glucosylceramidase
Catechol O-Methyltransferase
tau Proteins
Severity of Illness Index
Cohort Studies
Neuropsychological Tests
Genotype
Aged
Aged
80 and over
Middle Aged
Female
Male
Apolipoprotein E4
Genetic Variation
Genetic Association Studies
Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
Cognitive Dysfunction
Cognitive impairment
Genetics
NeuroX
Parkinson's disease
Human Genome
Aging
Basic Behavioral and Social Science
Behavioral and Social Science
Neurosciences
Parkinson's Disease
Neurodegenerative
Brain Disorders
Clinical Research
Aetiology
2.1 Biological and endogenous factors
Neurological
Clinical Sciences
Neurology & Neurosurgery
Language
Abstract
Cognitive impairment is a common and disabling problem in Parkinson's disease (PD). Identification of genetic variants that influence the presence or severity of cognitive deficits in PD might provide a clearer understanding of the pathophysiology underlying this important nonmotor feature. We genotyped 1105 PD patients from the PD Cognitive Genetics Consortium for 249,336 variants using the NeuroX array. Participants underwent assessments of learning and memory (Hopkins Verbal Learning Test-Revised [HVLT-R]), working memory/executive function (Letter-Number Sequencing and Trail Making Test [TMT] A and B), language processing (semantic and phonemic verbal fluency), visuospatial abilities (Benton Judgment of Line Orientation [JoLO]), and global cognitive function (Montreal Cognitive Assessment). For common variants, we used linear regression to test for association between genotype and cognitive performance with adjustment for important covariates. Rare variants were analyzed using the optimal unified sequence kernel association test. The significance threshold was defined as a false discovery rate-corrected p-value (PFDR) of 0.05. Eighteen common variants in 13 genomic regions exceeded the significance threshold for one of the cognitive tests. These included GBA rs2230288 (E326K; PFDR = 2.7 × 10-4) for JoLO, PARP4 rs9318600 (PFDR = 0.006), and rs9581094 (PFDR = 0.006) for HVLT-R total recall, and MTCL1 rs34877994 (PFDR = 0.01) for TMT B-A. Analysis of rare variants did not yield any significant gene regions. We have conducted the first large-scale PD cognitive genetics analysis and nominated several new putative susceptibility genes for cognitive impairment in PD. These results will require replication in independent PD cohorts.